NEW YORK, Nov. 23, 2016 /PRNewswire/ -- Pomerantz LLP is
investigating claims on behalf of investors of ProNAi Therapeutics,
Inc. ("ProNAi" or the "Company") (NASDAQ: DNAI). Such
investors are advised to contact Robert S.
Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
9980.
The investigation concerns whether ProNAi and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
[Click here to join a class action]
On June 6, 2016, ProNAi released
its interim results from the Wolverine Phase 2 trial of PNT2258 for
the treatment of relapsed or refractory (r/r) diffuse large B-cell
lymphoma (DLBCL). Nick Glover, the Company's President and
CEO, stated that "[a]lthough [PNT2258] observed modest efficacy ...
in [the] interim analysis of Wolverine," the Company has "decided
to suspend the development of PNT2258" because the results were not
"robust enough to justify continued development of the drug in
DLBCL."
On this news, ProNAi's share price fell $4.31, or 67.55%, to close at $2.07 on June 6,
2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los
Angeles, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz Firm pioneered the field of securities class actions.
Today, more than 80 years later, the Pomerantz Firm continues in
the tradition he established, fighting for the rights of the
victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of class members. See
www.pomerantzlaw.com
CONTACT:
Robert S.
Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pronai-therapeutics-inc---dnai-300368124.html
SOURCE Pomerantz LLP